Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;22(12):1832-1841.
doi: 10.1111/codi.15120. Epub 2020 Jun 11.

Botulinum toxin type A for the treatment of dyssynergic defaecation in adults: a systematic review

P Chaichanavichkij  1 , P F Vollebregt  1 , S M Scott  1 , C H Knowles  1
Affiliations

Botulinum toxin type A for the treatment of dyssynergic defaecation in adults: a systematic review

P Chaichanavichkij et al. Colorectal Dis. 2020 Dec.

Abstract

Aim: Dyssynergic defaecation (DD) is characterized by inappropriate coordination of the pelvic floor muscles during defaecation, resulting in impaired stool expulsion. The mainstay of treatment is biofeedback and alternative therapies are limited in those who do not respond. This systematic review evaluated botulinum toxin type A injection (BTXA) as a treatment option for dyssynergia.

Methods: PubMed, Embase and Cochrane Central Register of Controlled Trials were searched for studies evaluating adult patients with DD treated with BTXA injection into the puborectalis and/or external anal sphincter. All study designs, except case reports, were included in the review with no language restriction. Studies limited to patients with specific neurological diagnoses or with a follow-up period under 1 month were excluded. Study selection, assessment and data extraction were performed by two reviewers and results were synthesized narratively.

Results: Eleven studies (three randomized control trials) involving 248 participants were included. All studies used the transanal approach to deliver the injection, most commonly at the 3 and 9 o'clock positions using digital palpation for guidance. The most commonly used patient position was left lateral, and most studies did not use any anaesthesia. The dose of BTXA varied (Botox 12-100 units, Dysport 100-500 units), and outcomes measured were heterogeneous (global rating ± up to five investigations). Symptomatic improvement varied between 29.2% and 100% and adverse effects occurred in 0% to 70%.

Conclusion: The evidence to support using BTXA for DD is poor and only covers a transanal approach. Future studies should redress these limitations: heterogeneity of design, dose and outcome measures.

Keywords: Dyssynergia; botox; botulinum toxin; constipation; dyssynergic defaecation; puborectalis.

PubMed Disclaimer

References

    1. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol [Internet]. 2011; 106: 1582-91.
    1. Zarate N, Knowles CH, Newell M et al. In patients with slow transit constipation, the pattern of colonic transit delay does not differentiate between those with and without impaired rectal evacuation. Am J Gastroenterol 2008; 103: 427-34.
    1. Palit S, Thin N, Knowles CH, Lunniss PJ, Bharucha AE, Scott SM. Diagnostic disagreement between tests of evacuatory function: a prospective study of 100 constipated patients. Neurogastroenterol Motil 2016; 28: 1589-98.
    1. Rao SSC, Bharucha AE, Chiarioni G et al. Anorectal disorders. Gastroenterology [Internet]. 2016; 150: 1430-42. e4.
    1. Rao SSC, Tuteja AK, Vellema T, Kempf J, Stessman M. Dyssynergic defecation: demographics, symptoms, stool patterns, and quality of life. J Clin Gastroenterol 2004; 38: 680-5.

Publication types

Substances

LinkOut - more resources